News about Aprea Therapeutics Inc

Aprea Therapeutics, a prominent player in the field of oncology, has strategically advanced its clinical an...
Dec 30 2024
Aprea Therapeutics Advances in Oncology: ATRN-119 Dual Dosing Approach and Promising Next-Gen Inhibitors Aprea Therapeutics, a prominent player in the...

Aprea Therapeutics Navigates Financial Setbacks While Showcasing Scientific Progress at EORTC-NCI-AACR Conference
Oct 10 2024
In the ever-competitive healthcare sector, Aprea Therapeutics Inc finds itself at a pivotal moment. Recently, the company recorded a cumulative net lo...

Aprea Therapeutics Announces Engagement of Dr. Philippe Pultar as Senior Medical Advisor to Lead Development of WEE1 Inhibitor APR-1051 Amid New Clinical Trial Initiatives,
Oct 09 2024
Aprea Therapeutics Expands Expertise with Appointment of Philippe Pultar, MD, to Lead WEE1 Clinical Development Amid New Trial InitiativesAprea Therap...

Advancing Precision Oncology Aprea Therapeutics Harnesses the Power of DNA Damage Response in Cancer Treatment
Jun 17 2024
In a recent development, Aprea Therapeutics, a clinical-stage biopharmaceutical company dedicated to precision oncology through synthetic lethality, a...

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Pati...
May 28 2024
...

APREA Therapeutics Inc Reports Enhanced Operating Shortfall of $-4.6 Million in Latest Fiscal Period
May 14 2024
As the earnings cycle progresses and more companies report their financial results, Aprea Therapeutics Inc stands out as a beacon of hope in the Major...

Unleashing New Cancer Combatants: Aprea Therapeutics Breakthrough with Next-gen WEE1 and ATR Inhibitors
Apr 10 2024
The Potentials Unveiled - WEE1 Inhibitor APR-1051 & ATR Inhibitor ATRN-119Aprea Therapeutics, a leader in developing cutting-edge cancer therapeutics,...

Aprea Therapeutics Inc Reports Revenue of $0.583231 Million in Fourth Quarter of 20232.
Mar 26 2024
Aprea Therapeutics Inc, a leading biotechnology company, recently announced some key financial data for the fiscal interval closing December 31, 2023....

Aprea Therapeutics* Financial Health Shines Amidst Industry Challenges
Mar 11 2024
(Article Body)In a recent announcement made by Aprea Therapeutics Inc, the biotechnology company shared news of a private placement financin...

Promising Progress: Aprea Therapeutics Spearheads Precision Oncology with DNA Damage Response Agents
Jan 04 2024
In the field of oncology, precision medicine has revolutionized the way cancer is diagnosed and treated. One promising area of research is synthetic l...

Aprea Therapeutics Inc. Reports a Substantial Operating Deficit of $-3.52285 Million for Q3 2023
Nov 12 2023
The third quarter of 2023 has brought positive developments for Aprea Therapeutics Inc, a major player in the Pharmaceutical Preparations in...